On Thursday, H.C. Wainwright adjusted its outlook on IGM Biosciences (NASDAQ:IGMS), reducing the price target to $11 from the previous $12 while maintaining a Neutral rating. The adjustment follows the announcement of IGM Biosciences' second-quarter financial results, which revealed a net loss of $0.79 per share. This figure notably diverged from the initially estimated net gain of $0.21 per share, due primarily to collaboration revenue falling short of expectations.
During the second quarter of 2024, IGM Biosciences incurred research and development (R&D) expenses of $42.0 million and selling, general, and administrative (SG&A) expenses of $10.6 million. These figures were largely in line with H.C. Wainwright's prior estimates, with R&D expenses slightly below the anticipated $42.5 million.
The firm has now revised its full-year 2024 net loss projection for IGM Biosciences to $2.31 per share, an improvement from the previously estimated net loss of $3.27 per share.
IGM Biosciences concluded the second quarter of 2024 with approximately $256.4 million in cash reserves. This financial position is expected to sustain the company's operations into the second quarter of 2026. The company's current cash runway is anticipated to cover the period leading up to several clinical updates.
The company has guided full-year 2024 GAAP operating expenses, anticipating a range of $210-220 million, which includes an estimated $40 million allocated for stock-based compensation. After considering the increased long-term operating expenses, H.C. Wainwright reiterated its Neutral stance on IGM Biosciences' stock but adjusted the 12-month price target downward to reflect the latest financial data and projections.
In other recent news, IGM Biosciences has reported significant developments in its early-stage pipeline.
Morgan Stanley (NYSE:MS) maintained an Overweight rating on the company, highlighting the progress in the Phase 1b study of imvotamab for rheumatoid arthritis and systemic lupus erythematosus, and the completion of enrollment for aplitabart in a Phase 1a/1b study for colorectal cancer. RBC Capital also adjusted its outlook on IGM Biosciences, reducing the price target but maintaining an Outperform rating.
The company has also seen corporate developments, including the election of three Class II directors and the ratification of Deloitte & Touche LLP as its independent accounting firm for the fiscal year ending December 31, 2024. An amendment limiting the liability of certain officers was approved, and a stock option exchange program for employees was also approved.
Lastly, IGM Biosciences refined its collaboration with Sanofi (EPA:SASY) (NASDAQ:SNY), now focusing solely on immunology and inflammation targets.
InvestingPro Insights
As IGM Biosciences (NASDAQ:IGMS) navigates through its financial and operational challenges, insights from InvestingPro offer a deeper understanding of the company's current market position. With a market capitalization of $584.88 million, IGM Biosciences is trading at a high revenue valuation multiple, which could suggest investor optimism about the company's growth prospects. Despite reporting a substantial net loss per share in the second quarter of 2024, the company's revenue growth is notable, with a 74.0% increase over the last twelve months as of Q2 2024, and an even more impressive quarterly revenue growth of 179.91%.
InvestingPro Tips highlight that IGM Biosciences holds more cash than debt on its balance sheet and has liquid assets that exceed short-term obligations, providing some financial stability in the near term. Additionally, two analysts have revised their earnings upwards for the upcoming period, indicating potential confidence in the company's future performance. However, it is important to note that analysts do not expect IGM Biosciences to be profitable this year, and the company has been quickly burning through cash, which aligns with the net loss reported in the recent quarterly results.
Investors may also find the company's stock performance intriguing, with a strong return over the last month of 23.96% and a three-month return of 25.15%, reflecting recent positive sentiment in the market. It is worth mentioning that IGM Biosciences does not pay a dividend to shareholders, which could influence investment decisions for those seeking regular income from their investments.
To explore additional insights, there are more InvestingPro Tips available for IGM Biosciences at InvestingPro, which could further inform investment strategies and decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.